Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar‐associated protein 4
Authors:
- Bjørn Stæhr MadsenBMBjørn Stæhr Madsen
- Maja ThieleMTMaja Thiele
- Sönke DetlefsenSDSönke Detlefsen
- Maria KjærgaardMKMaria Kjærgaard
- Ditlev Nytoft RasmussenDRDitlev Nytoft Rasmussen
- Anders SchlosserASAnders Schlosser
- Uffe HolmskovUHUffe Holmskov
- Jonel TrebickaJTJonel Trebicka
- Grith Lykke SorensenGSGrith Lykke Sorensen
- Aleksander KragAKAleksander Krag
Open Access
- 27 April 2020
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 40 (7) , 1701-1712
Abstract
Background: Alcoholic liver disease (ALD) is a public health concern that is the cause of half of all cirrhosis‐related deaths. Early detection of fibrosis, ideally in the precirrhotic stage, is a key strategy for improving ALD outcomes and for preventing progression to cirrhosis. Previous studies identified the blood‐borne marker human microfibrillar‐associated protein 4 (MFAP4) as a biomarker for detection of hepatitis C virus (HCV)‐related fibrosis. Aim: To evaluate the diagnostic accuracy of MFAP4 to detect ALD‐induced fibrosis.Method: We performed a prospective, liver biopsy‐controlled study involving 266 patients with prior or current alcohol overuse. Patients were split into a training and a validation cohort.Results: MFAP4 was present in fibrotic hepatic tissue and serum MFAP4 levels increased with fibrosis grade. The area under the receiver operating characteristic curve (AUROC) for detection of cirrhosis was 0.91 (95% CI 0.85‐0.96) in the training cohort and 0.91 (95% CI 0.79‐1.00) in the validation cohort. For detection of advanced fibrosis, the AUROC was 0.88 (95% CI 0.81‐0.94) in the training cohort and 0.92 (95% CI 0.83‐1.00) in the validation cohort. The diagnostic accuracy did not differ between MFAP4 and the enhanced liver fibrosis (ELF) test or transient elastography (TE) in an intention‐to‐diagnose analysis. MFAP4 did not predict hepatic decompensation in a time‐to‐decompensation analysis in a subgroup of patients with cirrhosis.Conclusion: MFAP4 is a novel biomarker that can detect ALD‐related fibrosis with high accuracy.Keywords
Funding Information
- Toyota Foundation
This publication has 31 references indexed in Scilit:
- Localization of Microfibrillar-Associated Protein 4 (MFAP4) in Human Tissues: Clinical Evaluation of Serum MFAP4 and Its Association with Various Cardiovascular ConditionsPLOS ONE, 2013
- Feasibility of detection and intervention for alcohol-related liver disease in the community: the Alcohol and Liver Disease Detection study (ALDDeS)British Journal of General Practice, 2013
- Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of CirrhosisGastroenterology, 2013
- Incidence, etiology and mortality of cirrhosis: a population-based cohort studyScandinavian Journal of Gastroenterology, 2012
- Reduced Mortality Rates Following Elective Percutaneous Liver BiopsiesGastroenterology, 2010
- Alcohol‐related cirrhosis—early abstinence is a key factor in prognosis, even in the most severe casesAddiction, 2009
- Detection of novel biomarkers of liver cirrhosis by proteomic analysis #Hepatology, 2009
- Liver biopsy†Hepatology, 2009
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liverThe Lancet, 1995